According to a recent report by Meticulous Research®, the viral vaccines market is expected to reach $47.01 billion by 2031, growing at a CAGR of 1.9% from 2024 to 2031. This growth is driven by a robust pipeline of vaccine products, increased government emphasis on immunization programs, technological advancements in vaccine delivery, and the expanded use of inactivated vaccines in surgeries and treatments. Additionally, capacity expansions in biopharmaceuticals, a rising focus on therapeutic vaccines, the growing use of adjuvants, opportunities in emerging markets, and the development of stable, energy-efficient ultra-low temperature freezers are poised to create significant growth opportunities for market players.
